DK3169341T3 - Onkolytisk virus til ekspression af immun-checkpoint-modulatorer - Google Patents

Onkolytisk virus til ekspression af immun-checkpoint-modulatorer Download PDF

Info

Publication number
DK3169341T3
DK3169341T3 DK15738359.7T DK15738359T DK3169341T3 DK 3169341 T3 DK3169341 T3 DK 3169341T3 DK 15738359 T DK15738359 T DK 15738359T DK 3169341 T3 DK3169341 T3 DK 3169341T3
Authority
DK
Denmark
Prior art keywords
immun
expression
oncolytic virus
checkpoint modulators
checkpoint
Prior art date
Application number
DK15738359.7T
Other languages
English (en)
Inventor
Nathalie Silvestre
Michel Geist
Karola Rittner
Jean-Baptiste Marchand
Christine Thioudellet
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of DK3169341T3 publication Critical patent/DK3169341T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C12N15/8636—Vaccina virus vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02009—Uracil phosphoribosyltransferase (2.4.2.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01023—Ceramidase (3.5.1.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK15738359.7T 2014-07-16 2015-07-16 Onkolytisk virus til ekspression af immun-checkpoint-modulatorer DK3169341T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14306153 2014-07-16
PCT/EP2015/066263 WO2016008976A1 (en) 2014-07-16 2015-07-16 Oncolytic virus for expression of immune checkpoint modulators

Publications (1)

Publication Number Publication Date
DK3169341T3 true DK3169341T3 (da) 2019-08-05

Family

ID=51220528

Family Applications (2)

Application Number Title Priority Date Filing Date
DK19174121.4T DK3552615T3 (da) 2014-07-16 2015-07-16 Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
DK15738359.7T DK3169341T3 (da) 2014-07-16 2015-07-16 Onkolytisk virus til ekspression af immun-checkpoint-modulatorer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK19174121.4T DK3552615T3 (da) 2014-07-16 2015-07-16 Onkolytisk virus til ekspression af immun-checkpoint-modulatorer

Country Status (14)

Country Link
US (2) US10555981B2 (da)
EP (2) EP3169341B1 (da)
JP (2) JP6895374B2 (da)
CN (1) CN107208069A (da)
AU (2) AU2015289125B2 (da)
CA (2) CA2954841A1 (da)
DK (2) DK3552615T3 (da)
ES (2) ES2909957T3 (da)
HU (1) HUE045108T2 (da)
IL (1) IL250058A0 (da)
PL (1) PL3169341T3 (da)
PT (1) PT3169341T (da)
RU (1) RU2696312C2 (da)
WO (1) WO2016008976A1 (da)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3381942T (pt) * 2012-08-30 2021-05-24 Amgen Inc Método para o tratamento do melanoma que utiliza um vírus herpes simplex e um inibidor de checkpoint imunitário
JP6502959B2 (ja) 2013-12-12 2019-04-17 上海恒瑞医薬有限公司 Ｐｄ−１抗体、その抗原結合性断片及びそれらの医学的使用
PL3169341T3 (pl) * 2014-07-16 2019-12-31 Transgene Sa Wirus onkolityczny do ekspresji modulatorów punktu kontroli immunologicznej
CA2955084C (en) * 2014-07-16 2023-08-29 Transgene Sa Combination of oncolytic virus with immune checkpoint modulators
RU2716821C2 (ru) 2014-10-24 2020-03-17 Калиди Биотерапьютикс, Инк. Комбинированный иммунотерапевтический подход к лечению рака
CA2977660A1 (en) 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva) as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
PL3283508T3 (pl) 2015-04-17 2021-10-11 Alpine Immune Sciences, Inc. Białka immunomodulacyjne o dostrajalnym powinowactwie
CA2982896A1 (en) 2015-04-17 2016-10-20 Memorial Sloan Kettering Cancer Center Use of modified vaccinia ankara virus (mva) or mva with a deletion of virulence factor e8 as immunotherapeutic agent against solid tumors
ES2803655T3 (es) 2015-05-29 2021-01-28 Agenus Inc Aticuerpos anti-ctla-4 y métodos de uso de los mismos
US20200046671A1 (en) * 2015-06-29 2020-02-13 Regents Of The University Of Minnesota Apobec3b mutagenesis and immunotherapy
JP2018527895A (ja) 2015-06-29 2018-09-27 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 抗−ａｐｏｂｅｃ３抗体並びにその製造及び使用方法
KR20180040138A (ko) 2015-07-13 2018-04-19 싸이톰스 테라퓨틱스, 인크. 항pd-1 항체, 활성화 가능한 항pd-1 항체, 및 이들의 사용 방법
CN115212301A (zh) 2015-08-11 2022-10-21 卡利迪生物治疗有限公司 用以癌症治疗的天花疫苗
US11357742B2 (en) 2015-12-14 2022-06-14 X4 Pharmaceuticals, Inc. Methods for treating cancer
EP3389634B1 (en) 2015-12-14 2021-10-06 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP7055380B2 (ja) 2015-12-22 2022-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 免疫不全疾患を処置するための方法
ES2943150T3 (es) 2016-01-08 2023-06-09 Replimune Ltd Cepa de virus oncolítico
EP3405203A4 (en) * 2016-01-22 2019-07-24 X4 Pharmaceuticals, Inc. METHODS OF TREATING CANCER
CN116904404A (zh) 2016-01-27 2023-10-20 昂克诺斯公司 溶瘤病毒载体及其用途
MX2018010231A (es) 2016-02-25 2019-06-06 Memorial Sloan Kettering Cancer Center Mva recombinante o mvadele3l que expresa el flt3l humano y uso de los mismos como agentes inmunoterapéuticos contra tumores sólidos.
CN109152815B (zh) 2016-02-25 2022-10-18 纪念斯隆凯特琳癌症中心 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒
CA3019394A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
MX2018012472A (es) 2016-04-15 2019-08-12 Alpine Immune Sciences Inc Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
US11414491B2 (en) 2016-05-18 2022-08-16 Mayo Foundation For Medical Education And Research Targeting PD-L1 on tumor cells
EP3472129A4 (en) 2016-06-21 2019-12-04 X4 Pharmaceuticals, Inc. CXCR4 INHIBITORS AND USES THEREOF
JP7084624B2 (ja) 2016-06-21 2022-06-15 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
EP3808748A1 (en) 2016-06-21 2021-04-21 X4 Pharmaceuticals, Inc. Substituted piperidines as cxcr4-inhibitors
SG11201811600PA (en) 2016-06-30 2019-01-30 Oncorus Inc Pseudotyped oncolytic viral delivery of therapeutic polypeptides
JP6731646B2 (ja) * 2016-07-13 2020-07-29 国立大学法人鳥取大学 外来遺伝子発現ワクシニアウイルスの製造方法
US20220354888A1 (en) * 2016-08-03 2022-11-10 Aalborg Universitet ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
TW201825511A (zh) * 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現免疫檢查點調節子的溶瘤病毒
CN110072550A (zh) 2016-11-01 2019-07-30 德那翠丝有限公司 用于治疗脑癌的组合疗法
ES2963226T3 (es) 2016-12-07 2024-03-26 Agenus Inc Anticuerpos ANTI-CTLA-4 y métodos de uso de los mismos
JP2020510624A (ja) * 2016-12-12 2020-04-09 マルチビア インコーポレイテッド がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物
US11298420B2 (en) * 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
CN108261426B (zh) * 2017-01-04 2019-04-05 杭州康万达医药科技有限公司 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用
GB201700350D0 (en) * 2017-01-09 2017-02-22 Replimune Ltd Altered virus
CN110741081B (zh) * 2017-01-30 2024-07-23 埃皮辛特瑞柯斯公司 肿瘤选择性tata盒和caat盒突变体
RU2740713C1 (ru) 2017-02-28 2021-01-20 Генемедицине Ко., Лтд. Противораковая композиция, содержащая опухолеспецифический онколитический аденовирус и ингибитор контрольной точки иммунного ответа
WO2018209315A1 (en) 2017-05-12 2018-11-15 Memorial Sloan Kettering Cancer Center Vaccinia virus mutants useful for cancer immunotherapy
EP3630807A1 (en) 2017-05-25 2020-04-08 Leidos, Inc. Pd-1 and ctla-4 dual inhibitor peptides
RU2771110C2 (ru) 2017-07-26 2022-04-26 Онкорус, Инк. Онколитические вирусные векторы и их применение
CN109576231B (zh) * 2017-09-28 2022-03-25 北京康万达医药科技有限公司 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
WO2019074983A1 (en) 2017-10-10 2019-04-18 Alpine Immune Sciences, Inc. CTLA-4 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF
EP3697810A2 (en) 2017-10-18 2020-08-26 Alpine Immune Sciences, Inc. Variant icos ligand immunomodulatory proteins and related compositions and methods
MX2020003388A (es) * 2017-10-27 2020-08-03 Merck Sharp & Dohme Composiciones y metodos para tratar cancer hepatico.
EP3710018A4 (en) * 2017-11-16 2022-03-09 Virogin Biotech Canada Ltd ONCOLYTIC VIRUSES DECORATED BY A TARGETING FRACTION
CN108165536A (zh) * 2017-12-11 2018-06-15 浙江大学 一种重组溶瘤痘苗病毒及其制备方法与应用
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
BR112020013769A2 (pt) 2018-01-05 2020-12-01 Ottawa Hospital Research Institute vetores de ortopoxvírus modificados
AU2019208892B2 (en) * 2018-01-19 2022-02-03 Kolon Life Science, Inc. Recombinant vaccinia virus and pharmaceutical composition comprising same
KR20200116086A (ko) 2018-01-26 2020-10-08 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 종양 치료를 개선하기 위한 종양 미세환경에서 대사 조절인자의 발현
WO2019151836A1 (en) * 2018-02-05 2019-08-08 Sillajen, Inc. Oncolytic vaccinia virus expressing an immune checkpoint protein antagonist to treat cancer
AU2019226906B2 (en) * 2018-02-28 2023-02-02 Bionoxx Inc. Pharmaceutical composition for preventing or treating cancer comprising anticancer virus and hydroxyurea as effective components
CN108329378B (zh) * 2018-03-12 2020-09-25 华中农业大学 塞内卡谷病毒vp1蛋白、编码基因、杂交瘤细胞株和单克隆抗体及其应用
CA3093696A1 (en) * 2018-03-13 2019-09-19 Memorial Sloan Kettering Cancer Center Oncolytic vaccinia virus expressing immune checkpoint blockade for cancer immunotherapy
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
BR112021002639A2 (pt) * 2018-08-16 2021-05-11 Musc Foundation For Research Development vírus recombinantes do mixoma e usos dos mesmos
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
EP3617230A1 (en) * 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
CN113164538A (zh) * 2018-09-10 2021-07-23 上海锦斯生物技术有限公司 修饰的溶瘤病毒、其组合物和用途
CN111100846A (zh) * 2018-10-26 2020-05-05 上海元宋生物技术有限公司 表达pd-1结合蛋白的溶瘤病毒及其应用
SG11202103589XA (en) * 2018-10-31 2021-05-28 Humanigen Inc Materials and methods for treating cancer
BR112021007995A2 (pt) * 2018-11-01 2021-08-10 Bioinvent International Ab molécula de anticorpo antagonista, sequência de nucleotídeos isolada, plasmídeo, vírus, célula, uso de uma molécula de anticorpo, composição farmacêutica, método para tratar câncer ou uma infecção causada por um patógeno intracelular em um paciente
JP7329593B2 (ja) * 2018-11-06 2023-08-18 カリディ・バイオセラピューティクス・インコーポレイテッド 細胞媒介性腫瘍溶解性ウイルス治療のための増強された系
KR102686295B1 (ko) 2018-11-21 2024-07-19 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 아데노바이러스 및 아데노바이러스의 사용 방법
CN109627336A (zh) * 2018-12-20 2019-04-16 南京昂科利医药科技创新研究院有限公司 一种表达pd-l1单链抗体的新城疫溶瘤病毒的制备方法及应用
US20220380799A1 (en) * 2018-12-21 2022-12-01 Ottawa Hospital Research Institute Modified orthopoxvirus vectors
SG11202106898VA (en) 2018-12-28 2021-07-29 Transgene Sa M2-defective poxvirus
US20230193213A1 (en) * 2019-01-29 2023-06-22 Arno Thaller Recombinant oncolytic newcastle disease viruses with increased activity
CN109913425B (zh) * 2019-03-22 2021-05-11 中国人民解放军总医院第五医学中心 一种重组流感病毒拯救方法及其在肿瘤治疗中的应用
CA3134140A1 (en) * 2019-03-28 2020-10-01 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Oncolytic myxoma virus expressing fast p14 to treat hematological cancer
JP7381604B2 (ja) 2019-04-29 2023-11-15 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 癌を治療するための多価ｐｄ－ｌ１結合化合物
CA3141162A1 (en) 2019-05-22 2020-11-26 Leidos, Inc. Lag3 binding peptides
AU2019463579B2 (en) * 2019-08-26 2024-08-08 Bionoxx Inc. Pharmaceutical composition comprising vaccinia virus and hydroxyurea as active ingredient for treatment of cancer
WO2022026496A2 (en) 2020-07-31 2022-02-03 Leidos, Inc. Lag3 binding peptides
EP4225444A1 (en) 2020-10-12 2023-08-16 Leidos, Inc. Immunomodulatory peptides
CN112641798A (zh) * 2020-12-29 2021-04-13 武汉博威德生物技术有限公司 一种提高重组柯萨奇病毒溶瘤作用的方法
AU2022205429A1 (en) * 2021-01-11 2023-07-20 Seneca Therapeutics, Inc. Seneca valley virus combination therapy to treat a cancer refractory to a checkpoint inhibitor
EP4281549A1 (en) * 2021-01-19 2023-11-29 Seneca Therapeutics, Inc. Armed seneca valley virus oncolytic therapy compositions and methods thereof
CN114934065A (zh) * 2021-11-25 2022-08-23 浙江理工大学绍兴生物医药研究院有限公司 携带免疫检查点分子tim-3抗体基因的溶瘤腺病毒构建方法和应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2656800B1 (fr) 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5856153A (en) 1994-11-17 1999-01-05 Cayla Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
AU722624B2 (en) 1996-09-06 2000-08-10 Trustees Of The University Of Pennsylvania, The An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
WO1998056415A1 (en) 1997-06-11 1998-12-17 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
FR2777570A1 (fr) 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6322980B1 (en) 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
WO2001014424A2 (en) 1999-08-24 2001-03-01 Medarex, Inc. Human ctla-4 antibodies and their uses
WO2001066137A1 (en) 2000-03-07 2001-09-13 Merck & Co., Inc. Adenovirus formulations
JP4249013B2 (ja) 2001-07-31 2009-04-02 佑 本庶 Ｐｄ−１に対し特異性を有する物質
GB0128288D0 (en) 2001-11-27 2002-01-16 Siddall & Hilton Ltd Spring location means
CA2467365C (en) 2001-12-10 2012-11-20 Bavarian Nordic A/S Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
US7550140B2 (en) 2002-06-13 2009-06-23 Crucell Holland B.V. Antibody to the human OX40 receptor
EP3287144A1 (en) 2002-07-03 2018-02-28 ONO Pharmaceutical Co., Ltd. Immunopotentiating compositions
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
CA2532783C (en) 2003-07-21 2013-09-17 Transgene S.A. Polypeptide having an improved cytosine deaminase activity
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
CN101056646A (zh) * 2004-11-12 2007-10-17 拜耳先灵医药股份有限公司 重组新城疫病毒
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
KR101339628B1 (ko) 2005-05-09 2013-12-09 메다렉스, 인코포레이티드 예정 사멸 인자 1(ｐｄ-1)에 대한 인간 모노클로날 항체, 및 항-ｐｄ-1 항체를 단독 사용하거나 기타 면역 요법제와 병용한 암 치료 방법
EP2397155B1 (en) 2005-06-08 2017-12-13 Dana-Farber Cancer Institute, Inc. Methods and compositions for the treatment of persistent infections by inhibiting the programmed cell death 1 (PD-1)pathway
KR101357685B1 (ko) 2005-11-21 2014-02-06 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 재조합 바이러스용 안정화 제형
AU2007241023B2 (en) 2006-03-30 2013-11-28 University Of California Methods and compositions for localized secretion of anti-CTLA-4 antibodies
CA2656259C (en) 2006-06-20 2013-03-19 Transgene S.A. Process for producing poxviruses and poxvirus compositions
JP2009541236A (ja) 2006-06-20 2009-11-26 トランジェーヌ、ソシエテ、アノニム 組換えウイルスワクチン
GB0705245D0 (en) 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
JP2010526546A (ja) 2007-05-14 2010-08-05 バヴァリアン・ノルディック・アクティーゼルスカブ ワクシニアウイルス系及び組換えワクシニアウイルス系ワクチンの精製
BRPI0812913B8 (pt) 2007-06-18 2021-05-25 Merck Sharp & Dohme anticorpos monoclonais ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotideo, método para produzir os referidos anticorpos ou fragmentos de anticorpos, composição que os compreende e uso dos mesmos
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
AU2008328257B2 (en) * 2007-11-19 2013-08-22 Transgene Sa Poxviral oncolytic vectors
JP5710262B2 (ja) 2007-11-19 2015-04-30 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． ポックスウイルス腫瘍細胞崩壊性ベクター
US9687515B2 (en) * 2007-11-19 2017-06-27 Transgene S.A. Poxviral oncolytic vectors
NZ602498A (en) 2007-11-30 2014-08-29 Abbvie Inc Protein formulations and methods of making same
WO2009100521A1 (en) 2008-02-12 2009-08-20 Sanofi Pasteur Limited Methods using ion exchange and gel filtration chromatography for poxvirus purification
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
JP2012526532A (ja) 2009-05-12 2012-11-01 トランジェーヌ、ソシエテ、アノニム 不死化鳥類細胞系およびその用途
MX342017B (es) 2010-03-26 2016-09-09 Dartmouth College Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
DK2739293T3 (da) 2011-08-05 2020-08-24 Sillajen Biotherapeutics Inc Fremgangsmåder og sammensætninger til frembringelse af vaccinavirus
US20130071403A1 (en) 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
AU2013296919A1 (en) 2012-07-30 2015-01-22 Alex Wah Hin Yeung Cancer vaccine comprises tumor cells, an oncolytic virus vector and/or an immune checkpoint modulator
WO2014047350A1 (en) * 2012-09-20 2014-03-27 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
PL3169341T3 (pl) * 2014-07-16 2019-12-31 Transgene Sa Wirus onkolityczny do ekspresji modulatorów punktu kontroli immunologicznej
CN108165536A (zh) * 2017-12-11 2018-06-15 浙江大学 一种重组溶瘤痘苗病毒及其制备方法与应用
CA3093696A1 (en) * 2018-03-13 2019-09-19 Memorial Sloan Kettering Cancer Center Oncolytic vaccinia virus expressing immune checkpoint blockade for cancer immunotherapy
EP3617230A1 (en) * 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
CN110218707B (zh) * 2019-05-29 2021-10-22 上海市公共卫生临床中心 一种新型溶瘤病毒及其制备方法和应用

Also Published As

Publication number Publication date
US11779619B2 (en) 2023-10-10
US20200197457A1 (en) 2020-06-25
AU2015289125A1 (en) 2017-02-02
EP3169341B1 (en) 2019-06-05
EP3552615B8 (en) 2022-03-02
RU2696312C2 (ru) 2019-08-01
JP2017522025A (ja) 2017-08-10
RU2017103162A (ru) 2018-08-16
CA3190510A1 (en) 2016-01-21
EP3169341A1 (en) 2017-05-24
PL3169341T3 (pl) 2019-12-31
ES2909957T3 (es) 2022-05-11
CA2954841A1 (en) 2016-01-21
ES2743873T3 (es) 2020-02-21
EP3552615B1 (en) 2022-01-26
AU2020200541A1 (en) 2020-02-13
HUE045108T2 (hu) 2019-12-30
PT3169341T (pt) 2019-09-09
AU2020200541B2 (en) 2021-12-16
JP2021006048A (ja) 2021-01-21
US10555981B2 (en) 2020-02-11
DK3552615T3 (da) 2022-02-14
JP7077377B2 (ja) 2022-05-30
CN107208069A (zh) 2017-09-26
WO2016008976A1 (en) 2016-01-21
US20170157188A1 (en) 2017-06-08
AU2015289125B2 (en) 2019-11-28
EP3552615A1 (en) 2019-10-16
IL250058A0 (en) 2017-03-30
JP6895374B2 (ja) 2021-06-30
RU2017103162A3 (da) 2018-08-22

Similar Documents

Publication Publication Date Title
DK3169341T3 (da) Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
DK3400293T3 (da) Modificeret onkolytisk virus
DK3169340T3 (da) Kombination af onkolytisk virus med immun-checkpoint-modulatorer
DK3394033T3 (da) Heterocykliske forbindelser som immunmodulatorer
DK3331876T3 (da) Modulators of ror-gamma
DK3366295T3 (da) Fremgangsmåder til behandling af filoviridae virusinfektioner
DK3172319T3 (da) Coronavirus
DK3137169T3 (da) Hæmmere af lysin-specifik demethylase-1
BR112017001385A2 (pt) anticorpos anti-pd-1
DK3262071T3 (da) Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
DK3137605T3 (da) Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression
DK3110988T3 (da) Metoder til behandling af lithiumholdige materialer
DK3556775T3 (da) Anti-lag-3 antistoffer til behandling af hæmatologiske maligniteter
DK3102576T3 (da) Dihydropyrrolopyridininhibitorer af ror-gamma
DK3131902T3 (da) Forbindelser som ROR-gamma-modulatorer
DK3236881T3 (da) System til vaccination af fjerkræ
DK3079122T3 (da) Nuancering af cg-fremstillinger af materialer
DK3212642T3 (da) Amid-substituerede thiazoler som modulatorer af rorgammat
DK3130392T3 (da) Virusfjernelsesmembran
FR3027415B1 (fr) Modulateur de phase electro­optique
DK3511418T3 (da) Fremgangsmåde til nedbrydning af mannanholdige celluloseholdige materialer
DK3137449T3 (da) Fremgangsmåder til fremstilling af substituerede cycloseriner
DK3418273T3 (da) Derivater af flavagliner
DK3141052T3 (da) Konfiguration af beskyttelsesperiode til LTE HD-FDD
DK3161136T3 (da) Fremgangsmåde til berigelse af mikrovesikler